skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Treatment of patients with comorbid depression and diabetes with metformin and milnacipran

Review

(2036) Views  (540) Full article downloads

Authors: Peter Hofmann

Published Date August 2010 Volume 2010:6(Supplement 1) Pages 9 - 15
DOI: http://dx.doi.org/10.2147/NDT.S11775

Peter Hofmann
University Clinic of Psychiatry, Graz Medical University, Graz, Austria

Abstract: Depression is twice as frequent in patients with diabetes as in the general ­population, and has a negative impact on self-care, adherence to treatment, and the general prognosis of diabetes. This underscores the importance of screening all diabetic patients for depression and, if necessary, treating it with an effective antidepressant drug in parallel with standard diabetes ­treatment. In a recent study, a simple two-question screening tool was used to screen diabetic patients for comorbid depression. The effects of the serotonin and norepinephrine reuptake inhibitor antidepressant, milnacipran, on metabolic parameters and depressive ­symptoms in 64 diabetic patients with comorbid depression detected by this screen were ­studied. Patients received ­milnacipran for 6 months, in addition to standard diabetes treatment with metformin. At the end of the study, 72% of patients had responded to antidepressant treatment (≥50% reduction of baseline Beck Depression Score). The proportion of patients with <8% glycosylated hemoglobin HbA1c (a common indication in diabetes of the need for intensive therapeutic intervention) had decreased significantly from 46.6% at baseline to 6.9%. HbA1c, fasting blood glucose, body mass index, total and low-density lipoprotein cholesterol, and serum triglyceride levels were all significantly decreased in patients with an antidepressant response, but not in patients whose depressive symptoms had not responded to milnacipran.

Keywords: depression, diabetes, milnacipran, serotonin, norepinephrine, reuptake inhibitors





 

Other articles by Dr Mike Briley

Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study
Antidepressant therapy with milnacipran and venlafaxine
Choking risk among psychiatric inpatients
Editorial Foreword - Milnacipran: recent findings in depression
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
Improvement of the noradrenergic symptom cluster following treatment with milnacipran
Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
Milnacipran: a unique antidepressant?
Milnacipran: recent findings in depression
Noradrenergic symptom cluster in depression
Psychiatric diagnoses in patients with burning mouth syndrome and atypical odontalgia referred from psychiatric to dental facilities
Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series
Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran
The importance of norepinephrine in depression
The increasing burden of depression
The noradrenergic symptom cluster: clinical expression and neuropharmacology


Readers of this article also read:

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
Milnacipran: recent findings in depression
Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran
Antidepressant therapy with milnacipran and venlafaxine
Milnacipran: a unique antidepressant?
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?